| Dr Anjali Koka, MD | |
|
55 Fruit St, Mgh Department Of Anesthesia And Critical Care, Boston, MA 02114-2621 | |
| (617) 746-6000 | |
| Not Available |
| Full Name | Dr Anjali Koka |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Location | 55 Fruit St, Boston, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144458902 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 232946 (Massachusetts) | Primary |
| Entity Name | Chmc Anesthesia Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831268754 PECOS PAC ID: 0446155568 Enrollment ID: O20031203000162 |
News Archive
Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.
Injury and repair are part of the normal life cycle of any tissue or organ in the human body. However, if macroscopic tears or breaks occur in the bones or joints, for instance, the effects are immediately perceptible. Not so with chromosomes, which contain the DNA of life. Both extremely valuable and extremely fragile, DNA is the focus of highly efficient repair proteins.
CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review its Biologics License Application (BLA) for a human 4-factor prothrombin complex concentrate (PCC) for the urgent reversal of vitamin K-antagonist therapy (i.e., warfarin) in patients with acute major bleeding. If approved by the FDA, the CSL Behring 4-factor PCC would be the first agent of its kind available in the United States.
The risk of developing major depressive disorder (MDD) surges during adolescence-particularly for girls. Cognitive behavioral therapy (CBT) can be an effective treatment, but only about half of girls diagnosed with depression show significant improvement.
Dyadic International, Inc., a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, today announced financial results for the second quarter ended June 30, 2014.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Anjali Koka, MD 14 Pilgrim Dr, Winchester, MA 01890-3371 Ph: () - | Dr Anjali Koka, MD 55 Fruit St, Mgh Department Of Anesthesia And Critical Care, Boston, MA 02114-2621 Ph: (617) 746-6000 |
News Archive
Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.
Injury and repair are part of the normal life cycle of any tissue or organ in the human body. However, if macroscopic tears or breaks occur in the bones or joints, for instance, the effects are immediately perceptible. Not so with chromosomes, which contain the DNA of life. Both extremely valuable and extremely fragile, DNA is the focus of highly efficient repair proteins.
CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review its Biologics License Application (BLA) for a human 4-factor prothrombin complex concentrate (PCC) for the urgent reversal of vitamin K-antagonist therapy (i.e., warfarin) in patients with acute major bleeding. If approved by the FDA, the CSL Behring 4-factor PCC would be the first agent of its kind available in the United States.
The risk of developing major depressive disorder (MDD) surges during adolescence-particularly for girls. Cognitive behavioral therapy (CBT) can be an effective treatment, but only about half of girls diagnosed with depression show significant improvement.
Dyadic International, Inc., a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, today announced financial results for the second quarter ended June 30, 2014.
› Verified 7 days ago
Stephen G. Flynn, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6000 | |
Dr. Dusan Hanidziar, M.D., PH.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 55 Fruit St, Gray-bigelow 444, Boston, MA 02114 Phone: 617-726-3030 | |
Dr. Michael Christopher Lubrano, M.D., M.P.H. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-732-8210 | |
Vahid Kiarad, M.D Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 330 Brookline Ave, Boston, MA 02215 Phone: 617-667-7000 | |
Kendrick M Shaw, MD, PHD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 Phone: 617-726-3030 | |
John William Carl Carter Mallett, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-732-5500 | |
Dr. David Joswick, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 800 Washington St, Boston, MA 02111 Phone: 617-636-5000 |